Global burden of vaccine-associated uveitis and their related vaccines, 1967-2023.
Where this comes from
- Record sourced from PubMed, PMID 39424330.
- Also identified by DOI 10.1136/bjo-2024-325985.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although uveitis after vaccination is rare, reports emerged during the COVID-19 pandemic. We used the pharmacovigilance case/non-case study from 1967 to 2023 to assess the association between vaccines and uveitis. We identified a significant signal for uveitis (reporting OR (ROR), 1.64; information component (IC)<sub>025</sub>, 0.66) with 1508 reports. This association is pronounced in females of all ages after childhood. Specifically, the COVID-19 messenger RNA vaccines showed the strongest disproportionality signal (ROR, 5.76; IC<sub>025</sub>, 2.33), followed by hepatitis B, papillomavirus, Ad (Adenovirus) 5-vectored COVID-19 and influenza vaccines. These findings underscore the importance of surveillance in the postmarketing phase to manage potential adverse events associated with vaccine administration.
Medical subject headings
- Uveitis
- COVID-19 Vaccines
- COVID-19
- Vaccination